We are live on ! Find out more
AZN icon

AstraZeneca

174.35 USD
-1.06
0.6%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
174.30
-0.05
0.03%
1 day
-0.6%
5 days
-6.72%
1 month
3.28%
3 months
5.99%
6 months
-6.99%
Year to date
-4.8%
1 year
-1.7%
5 years
54.16%
10 years
218.86%
 

About: A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Employees: 96,100

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 55%
Neutral 35.9%
Negative 9.2%
Positive
Zacks Investment Research
22 hours ago
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
AstraZeneca gains FDA priority review for its Sone-Ve cancer drug application, with a regulatory decision expected in Q2 2027.
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
Positive
Seeking Alpha
2 days ago
Allspring Large Cap Growth Fund Q3 2026 Portfolio Activity
We continue to hold Twilio stock and believe the emergence of agentic AI is expanding its addressable market. Sandisk is positioned to benefit from a growing addressable market, rising AI demand, and improved earnings visibility. With spending on data centers expected to grow significantly in the future, we believe that Vertiv remains well positioned to beat expectations and deliver strong future growth.
Allspring Large Cap Growth Fund Q3 2026 Portfolio Activity
Positive
Zacks Investment Research
3 days ago
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
Positive
Zacks Investment Research
4 days ago
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
Negative
Barrons
5 days ago
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Neutral
Business Wire
7 days ago
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's ​IMFINZI® (durvalumab)​ in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted by the Food and Drug Administration af.
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
Negative
Reuters
7 days ago
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
AstraZeneca has cut about 600 ​jobs from its respiratory and ‌immunology commercial teams in the US as part of its three-year cost-savings initiative, ​Bloomberg News reported on Friday, citing ​people familiar with the matter.
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
Positive
Reuters
8 days ago
EU panel backs AstraZeneca hypertension drug baxdrostat
AstraZeneca said on Friday a European medicines committee had backed its ​hypertension pill baxdrostat, branded as Baxfendy, ‌for marketing authorisation, potentially making it the first drug of its class to reach ​patients in the European Union.
EU panel backs AstraZeneca hypertension drug baxdrostat
Neutral
Seeking Alpha
10 days ago
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca's specialty medicines in Oncology, Respiratory, and Rare Diseases are driving double-digit growth, offsetting patent cliff impacts in legacy drugs. AZN trades at a significant valuation discount: a non-GAAP FWD P/E of 18.46x and a PEG of 1.28, below sector medians, supporting a BUY rating. Q3 FY2026 saw 7% revenue growth and 4 percentage point core margin expansion, with strong pipeline momentum and 12 positive Phase III readouts.
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
Neutral
Business Wire
10 days ago
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community Solutions Challenge (CSC), ACT on Health Equity supports nonprofit programs focused on advancing health.
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
Price charts implemented using Lightweight Charts™